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Abstract
Background: Voltage-gated sodium channels (VGSCs) play pivotal roles in the metastatic process in several
cancers, including breast and colon cancers. Sigma-1 receptors are known to interact and form complexes with a
number of ion channels aiding the delivery of the channel protein to the plasma membrane. Drugs that bind the
Sigma-1 receptor are hypothesized to affect this process and reduce the delivery of the channel protein to the
plasma membrane, in turn reducing the metastatic potential of the cells.
Methods: Human colon cancer cell line SW620 was utilized as a model to investigate the interaction between
the neonatal VGSC (nNav1.5) and the Sigma-1 receptor. This was accomplished using drugs that bind the
Sigma-1 receptor, Sigma-1 receptor silencing, and antibodies that bind and block the nNav1.5 channel.
Results: Sigma-1 receptor drugs SKF10047 and dimethyl tryptamine were found to alter (reduce) the adhesion
of these cells by 46–54% at a 20lM drug concentration. In a similar manner, gene silencing of the Sigma-1
receptor had a similar effect in reducing the adhesion of these cells to collagen-coated plates by 30%. The
Sigma-1 receptor was found to be in a complex with nNav1.5 in SW620 cells, and Sigma-1 drugs or gene
silencing of the Sigma-1 receptor results in a reduction of the surface expression of nNav1.5 by*50%. Culture
of SW620 cells under hypoxic conditions resulted in upregulation of the Sigma-1 receptor and nNav1.5. In
addition, surface expression of nNav1.5 protein increased under hypoxic culture conditions and this was
inhibited by the application of SKF10047.
Conclusions: It is proposed that in colon cancer cells, upregulated Sigma-1 receptor expression in hypoxia led
to increased nNav1.5 protein expression at the plasma membrane and resulted in the cells switching to a more
invasive state.
Keywords: Sigma-1 receptor, sodium channel, colon cancer
Introduction
Ion channels play many essential physiological rolesin the human body. In the past 20 years, their importance in
many features of cancer cell biology, including proliferation,
adhesion, migration, and invasion, has been reported. Given
that ion channels are also pharmacological targets, many
researchers have attempted to utilize drugs that modulate ion
channels to target specific processes that these ion channels
have been demonstrated to act upon.1 Within cancer cells, we
are starting to elucidate the exact mechanisms of how ion
channels may alter the cellular pathophysiology. Functional
expression of voltage-gated sodium channels (VGSCs) in
breast, prostate, lung, colon, and cervical (and other) cancers
has been reported by many groups.2–10 What has come to
light is that VGSC expression appears to be a ‘‘switch’’ that
results in cancer cells becoming highly invasive.11
VGSCs can be targeted/blocked with pharmacological
agents and, utilizing mouse models, it was shown that this
results in suppression of local invasion and metastasis.12,13
For breast and colon cancer cell lines, a neonatal splice
version Nav1.5 (nNav1.5) appears to be the predominant
subtype of VGSC.6,11 In the colon cancer cell line SW620,
hypoxia drives invasiveness, possibly through the persistent
current component of nNav1.5.6 In a previous publication, we
have documented that in breast cancer cell lines, nNav1.5
channels interact with and are modulated by Sigma-1 recep-
tors14 and this interaction alters the metastatic potential of
these cells.
Sigma-1 receptors are transmembrane proteins that appear
to act as molecular chaperones. The Sigma-1 receptor is
present in multiple locations within the cell, including in the
endoplasmic reticulum, plasma membrane, and perinuclear
areas.15 The chaperone activity of Sigma-1 receptors affects
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various ‘‘client’’ proteins, which include the IP3 receptor,
voltage-gated ion channels, and ankyrin (for reviews15,16).
The natural ligand for these receptors remains elusive but
some evidence indicates that dimethyl tryptamine (DMT)
may interact with Sigma-1 receptors in the brain.17,18 How-
ever, a wide range of antidepressants, antipsychotics, opiates,
and alkaloids also bind to Sigma-1 receptors with a variety
of affinities.19,20
There have been many studies documenting ion channel
modulation by Sigma-1 receptors. This modulation is re-
ported to be independent of G-proteins, cytoplasmic factors,
and protein phosphorylation.21 Patch clamp studies indicate
that for modulation to occur, the ion channel and Sigma-1
receptor must be in close proximity most likely in a molecular
complex.22 The VGSC found in cardiac cells (Nav1.5) is
modulated by Sigma-1 receptors.23 Furthermore, Sigma-1
receptors and Nav1.5 channels form complexes with a four-
fold symmetry as revealed by atomic force microscopy.24
Within MDA-MB-231 cells, The Sigma-1 receptor was found
to form complexes with Nav1.5 in these cells by immuno-
precipitation experiments and modulate the current density
of the channels.24 This led to a hypothesis according to which
Sigma-1 receptor ligands act on the Sigma-1 receptor and by
doing so change the invasive potential of breast cancer cells
in association with Nav1.5 channels.14
Hypothetically, under normal physiological conditions,
Sigma-1 receptors are inactive, but under cellular stress act to
modulate ‘‘client’’ proteins such as voltage-gated ion channels,
altering the electrical plasticity of the cells and hence pro-
moting cellular survival.25 Support for this hypothesis include
studies that Sigma-1 silencing suppresses recovery following
experimental stroke26 and promotes retinal degeneration after
acute optic nerve damage.18 A comparable mechanism by
which cancer cells utilize the Sigma-1 receptor to modulate ion
channels and alter their behavior in response to the tumor
microenvironment has been proposed.16
Given the demonstrated role of nNav1.5 in the metastasis
of colon cancer cells6 and previous experimentation in breast
cancer cells indicating a functional link between nNav1.5 and
Sigma-1 receptors, we aimed (1) to investigate Sigma-1 re-
ceptors and nNav1.5 in colon cancer cells and their interac-
tion and (2) to elucidate whether the action of Sigma-1 drugs
on colon cancer cells could occur via an interaction with
nNav1.5 and hence alter the invasive properties of these cells.
Methods
Cell culture
The human colon cancer cell line SW620, which was ob-
tained from LGC Standards (Middlesex, UK), was main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with the addition of 5% fetal calf serum, 4 mmol/L glutamine,
and antibiotics (penicillin/streptomycin). This cell line was
cultured in a 37C carbon dioxide (CO2) incubator and split
every 7 days. Hypoxia (1% oxygen) was induced for 24 h in a
dedicated incubator (Micro Galaxy; RS Biotech Laboratory
Equipment Ltd., Irvine, UK).
Pharmacological agents
Tetrodotoxin (TTX) was obtained from Tocris (Bristol,
UK). Sigma-1 receptor drugs SKF10047 and 5-methyl-DMT
were suspended with a 50% mixture of ethanol and water.
Control cells were also treated with this mixture. Both Sigma-
1 receptor ligands were obtained from Sigma-Aldrich (Gil-
lingham, UK).
Antibodies
A polyclonal antibody to nNav1.5 was produced as de-
scribed previously.14 The Sigma-1 receptor antibody was
described previously.27 Hif-1 antibody (H1alpha67 mono-
clonal) was obtained from Thermo Fisher (Hemel Hemp-
stead, UK). The mouse anti-Nav1.5 antibody was obtained
from Abcam (Cambridge, UK).
Gene silencing
Construction and verification of vectors to silence Sigma-1
receptors utilizing the pSilencer RNAi vector were described
previously.27 A Sigma-1 randomized sequence in the same
vector was utilized as a control. FuGENE HD (Roche, Wel-
wyn Garden City, UK) and Opti-MEM (Thermo Fisher) were
used to transfect the vectors into SW620 cells and efficiency
was monitored using the plasmid pHr-GFP, which was co-
transfected into cells. Silencing was verified by Western
blotting and the efficiency was quantified using a cell-based
enzyme-linked immunosorbent assay (ELISA) (see details in
Cell ELISA protocol section) with an anti-Sigma-1-specific
antibody. Overall silencing efficiencies of more than 80%
were achieved.
Proliferation assay
Cells at a concentration of 0.5 · 105 cells per mL in
maintenance media were aliquoted into 24-well plates. After
16 h, the media were replaced with 1 mL of media containing
SKF10047, N-methyl-DMT, or control treatment. After 72 h
at 37C, cell proliferation was determined using a crystal
violet assay. Cell proliferation was quantified by measuring
absorbance at 50 nm using growth media only as a blank.
Crystal violet assay
Medium was aspirated and the cells were washed three
times with phosphate-buffered saline (PBS). Crystal violet
stain (5 mg/mL in 20% methanol) was added to each well
(500lL/well) and incubated for 10 min at room temperature.
Subsequently, the cells were washed three times by carefully
submerging them in a tank containing water. The plates were
inverted and tapped dry on tissue paper. Subsequently, a
solubilization buffer (1% sodium dodecyl sulfate [SDS]) was
added (500lL/well) and the plates were shaken for 30 min at
room temperature. The absorbance of each plate was mea-
sured using a plate reader set at 570 nm. As a control, blank
wells without cells were also stained.
Adhesion assay
Cells were plated into 100 mm plates at a concentration of
1.5 · 106 cells in 10 mL of maintenance media and incubated
for 16 h. Following this media with Sigma-1 drugs or control
treatment or in some experiments, gene silencing was per-
formed as described above. After 24 h at 37C, cells were
washed with PBS and subsequently treated with PBS, which
contained 10 mM ethylenediaminetetraacetic acid (EDTA)
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for 15 min at 37C. Following detachment, the cells were
centrifuged at 1200 rpm for 5 min. The cell pellet was sus-
pended in 2 mL of growth media and quantified. The cells
were counted and adjusted to 5· 105 cells per mL. Twenty-
four-well plates, which had been precoated with collagen,
were seeded with the cell suspension at a concentration of
2.5 · 105 cells per well and incubated for 60 min at 37C. The
wells were washed three times with PBS and inverted onto
filter paper. Crystal violet was used to stain the cells and
absorbance at 570 nm was determined. Collagen coating of
plates occurred using 125lg/mL of collagen in PBS for 1 h at
37C. Subsequently, the plates were washed three times with
PBS followed by once with DMEM.
Transverse migration assay
PBS with 10 mM EDTA was used to detach the SW620
cells following incubation in media without serum for 24 h.
The cells were resuspended following centrifugation in me-
dia free of serum at a concentration of 2 · 106 cells per mL.
To the top chamber of 8-lm pore, 24-well migration plates
(Sigma-Aldrich), 100 lL of cells, were pipetted with either
SKF10047 or DMT, and to the bottom chamber, 500 lL of
maintenance media was added. Control wells without drugs
were also included. Cells were incubated at 37C for 24 h.
Following incubation, media were removed from the top
chamber and washed with PBS. Subsequently, the bottom
chamber was also aspirated and washed with PBS, which was
replaced with 500lL of PBS-EDTA containing 10 lM
calcein-AM (Thermo Fisher) and incubated for 1 h at 37 C in
a CO2 incubator. Plates were shaken for 10 min at room
temperature and following this the top chamber was removed
and the plate was read at 480 nm excitation and 520 nm
emission in a fluorescence plate reader.
Western blotting
Protein extracts from SW620 cells were prepared utilizing
an RIPA buffer containing 1% Triton-X and a mix of pro-
teinase inhibitors (Roche). Extracts from cells were adjusted
to a concentration of 1 mg/mL, mixed with SDS sample
buffer (Thermo Fisher), incubated at 95C for 10 min, and
10 lg of total protein was pipetted onto Tris-glycine acryl-
amide gradient minigels (Thermo Fisher). Following sepa-
ration for *1 h, the proteins in the gels were transferred to
polyvinylidene difluoride membranes for 2 h (for Sigma-1
receptor) or 8 h (for nNav1.5) at 4C. Transfer of proteins was
visualized by Ponceau red staining (Sigma-Aldrich). Mem-
branes were washed with PBS for 5 min and then ‘‘blocked’’
with PBS containing a mix of 2% bovine serum albumin
(BSA) and 2% skimmed milk for 2 h at room temperature.
Specific antibodies to Sigma-1 receptor or nNav1.5 were
utilized to probe the blots at a concentration of 5lg/mL in
PBS with 0.1% Tween (PBST), 1% skimmed milk, and 1%
BSA. The membranes were incubated with the antibodies
overnight at 4C. Blots were washed with four 5-min incu-
bations with PBST at room temperature on an orbital shaker.
Anti-rabbit horseradish peroxidase-conjugated secondary
antibodies (at the manufacturers’ suggested concentrations)
diluted in PBST with 1% skimmed milk and 1% BSA were
added for 24 h at 4C. The blots were washed as before and
then developed with an enhanced chemiluminescence Wes-
tern Blot Kit (Amersham, UK).
Immunocytochemistry
Glass coverslips placed in 35 mm culture dishes were
coated with poly-L-lysine (50 lg/mL). SW620 cells were
seeded into the wells at 1 · 106 cells per dish and subse-
quently placed in a tissue culture incubator for 24 h. The cells
were washed three times with Hanks buffered saline solution
(HBSS) and then treated with 4% paraformaldehyde for
8 min. Following three washing steps using PBS, cells were
treated with PBS containing 0.1% saponin for 10 min to per-
meabilize them, which was followed by another three washes
with PBS. In cases where surface expression of nNav1.5 was
investigated, the cells were not fixed with paraformaldehyde or
permeabilized with saponin at this stage. All cells were incu-
bated with 4% BSA in PBS for 30 min. Subsequently, anti-
bodies to either Sigma-1 or nNav1.5 were added for 1 h at a
concentration of 0.5lg/mL, at room temperature, for fixed
cells and 5lg/mL for live cells. For controls, purified rabbit
immunoglobulin G (IgG) at an equivalent concentration was
used. Cells prepared for visualization of surface staining were
washed three times with PBS and then fixed with 4% para-
formaldehyde at room temperature for 8 min, followed by
three washes with PBS at this stage. All cells were washed
three times with PBS containing 0.1% Tween and then stained
with the anti-rabbit antibody with fluorochromes attached, for
4 h at 4C. After a further three washes, the cells were mounted
with Vectashield (Vector Labs, Peterborough, UK) and ana-
lyzed by florescence microscopy.
Cell ELISA protocol
SW620 cells were plated into poly-L-lysine-treated 24-
well plates at 0.4 · 105 cells per well. The cells were washed
twice with HBSS and then either fixed with 4% parafor-
maldehyde for 8 min at 4C followed by a permeabilization
step with 0.1% saponin in PBS for 12 min at 4C or for sur-
face staining the cells were stained live without fixation or
permeabilization. Cells were incubated with 3% BSA in
HBSS buffer for 30 min at 4C followed by washing three
times with HBSS buffer. Subsequently, 0.5 lg/mL of the
primary antibody (nNav1.5, Sigma-1 receptor, or HIF-1) in
PBS with 5% BSA was added for 1 h at 37C. However, for
live stained cells, 5 lg/mL of nNav1.5 antibody was utilized.
At this stage, live cells were treated with 4% paraformalde-
hyde for 8 min at 4C followed by washing three times with
PBS containing 4% BSA. The cells were incubated with anti-
rabbit IgG Texas Red (1/50 dilution) (Sigma-Aldrich) in
1 mL of HBSS containing 4% BSA for 4 h at room temper-
ature. Following washing of cell three times in PBS, fluo-
rescence was quantified with a fluorescence plate reader. To
take into account differences in cell proliferation/adhesion
between treatments, cells were subsequently stained with
crystal violet and values adjusted accordingly.
Immunoprecipitation
Protein extracts from SW620 cells were prepared utilizing
an RIPA buffer containing 1% Triton-X and a mix of pro-
teinase inhibitors (Roche). The extract was quantified and
adjusted to a concentration of 1 mg/mL. Either mouse anti-
Nav1.5 or a rabbit anti-Sigma-1 receptor immunoprecipitat-
ing antibody was added at a final concentration of 3 lg/mL
for 16 h at 4C. Protein-A beads were added and incubated
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with mixing for 2 h at 4C. Spin columns (Thermo Fisher)
were utilized to collect and wash the beads and the captured
immunocomplexes. The beads were washed three times with
PBS, and subsequently, the beads were incubated with SDS-
polyacrylamide gel electrophoresis (PAGE) loading dye
(Sigma-Aldrich) for 5 min. The samples were heated to 95C
for 8 min and separated using SDS-PAGE gels. Controls in-
cluded performing the pull-down in the presence of a non-
specific IgG antibody.
Data analysis
Means were calculated for all samples along with standard
error of the means.
One-way analysis of variance test was utilized to establish
statistical significance, with differences being taken as sig-
nificant when p< 0.05.
Results
Proliferation
Proliferation of SW620 cells was determined in the pres-
ence of agents with a preference for binding to Sigma-1 re-
ceptors.15 SKF10047 or 5-methyl-DMT at concentrations of
100–1lM was incubated with the cells (Fig. 1) and prolifer-
ation was determined after 3 days in the presence of drugs
using a crystal violet assay. At concentrations of 20, 5, and
1lM for both SKF10047 and 5-methyl-DMT, no significant
difference was observed. At the higher concentration of
100lM, significant 28% and 27% reductions in cell prolifer-
ation were recorded for SKF10047 and 5-methyl-DMT, re-
spectively (F= 51 p= 3.2· 10-5; F= 21 p= 9.9· 10-4; n= 6).
Migration
Migration plays an important role in the capability of cells
to metastasize and develop secondary tumors. SKF10047 or
5-methyl-DMT was applied to SW620 cells at concentrations
of 100–1 lM (Fig. 2) using a transwell assay. For SKF10047
at lower concentrations of 1 and 5 lM, small reductions in
migration of 4% and 7% were recorded although these were
not significant. At the higher concentrations of 20 and
100lM, significant reductions of 13% and 20% in migration
were observed (F = 13 p= 0.017; F = 13 p = 0.011; n = 6). For
5-methyl-DMT, a significant reduction (21%) in migration
was only observed at the highest concentration of 100 lM
(F = 16 p = 0.006; n = 6). At the other concentrations of
DMT, changes in adhesion were observed with an increase of
FIG. 1. Effect of Sigma-1 drugs on proliferation of SW620 cells. Cells were treated with (A) either SKF10047 or (B) 5-
methyl-DMT at concentrations of 100, 20, 5, and 1 lM as indicated for 3 days. Proliferation was quantified as absorbance at
570 nm with a crystal violet assay (n = 6). Experiments with a significant difference from the respective control treatment are
marked with an asterisk ( p < 0.05). DMT, dimethyl tryptamine; OD, optical density.
FIG. 2. Effect of Sigma-1 drugs on migration of SW620 cells. Cells were treated with SKF10047 (A) or 5-methyl-DMT
(B) at concentrations of 100, 20, 5, and 1lM for 24 h as indicated and tested using transwell migration (n = 6). Migrated
cells were labeled with calcein-A and quantified as fluorescent emission measured at 520 nm and expressed as RFU.
Experiments with a significant difference from the respective control treatment are marked with an asterisk ( p < 0.05). RFU,
relative fluorescent units.
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adhesion of 2% at 1 lM, and decreases of adhesion of 3% and
10% for the 5 and 10 lM concentrations. However, these
effects were not statistically significant.
Adhesion
Adhesion to an extracellular matrix is an important de-
terminant for invasive cells. SKF10047 or 5-methyl-DMT at
concentrations of 100–1 lM was incubated with the cells for
24 h (Fig. 3) and the attachment to collagen-coated plates was
measured. SKF10047 at concentrations of 5, 20, and 100lM
reduced the adhesion of SW620 cells by 18%, 46%, and 55%,
respectively (F = 6.6 p= 0.033; F = 47 p = 1.3 · 10-4; F= 118
p = 4.5 · 10-6; n = 5; Fig. 3A). 5-Methyl-DMT at concen-
trations of 20 and 50lM also reduced the adhesion of
SW620 cells by 28% and 54% (F = 14.8 p = 0.003; F= 146
p = 2.7 · 10-7; n = 6; Fig. 3B). These results are comparable
with the results obtained for breast cancer cell lines MDA-
MB-231 and MDA-MB-468.14
Sigma-1 receptor silencing in SW620 was utilized to
confirm that the effects on adhesion were directly through the
effect of these drugs on the Sigma-1 receptor. A significant
reduction in adhesion of 30% was observed compared with
the controls (F = 18.8 p= 0.003; n = 5; Fig. 3C). A greater
effect on adhesion was not measured when 20lM SKF10047
was simultaneously added to Sigma-1 receptor-silenced cells
(Fig. 3C). To confirm that the adhesion of cells was capable
of being reduced further, TTX was utilized and a significant
reduction (57%) in adhesion was recorded in comparison
with all other treatments (F = 13.8 p = 0.0046; n = 6). These
experiments indicate that SKF10047 is directly acting on the
Sigma-1 receptor.
Interaction between Sigma-1 and VGSC (nNav1.5)
in SW620 cells
Sigma-1 receptors interact with Nav1.5 channel in breast
cancer cell lines,14 cardiomyocytes, or in HEK-293 cells
expressing both proteins.23 Ability of a ‘‘blocking’’ antibody
to nNav1.5 to reduce the adhesion of SW620 was first de-
termined (Fig. 4A). Using different amounts of this antibody
(100–1 ng/mL), cells were incubated for 24 h and adhesion to
collagen was evaluated. A reduction in adhesion was ob-
served with 100, 20, and 5 ng/mL antibody causing a re-
duction of 63%, 35%, and 20%, respectively, found to be
significant ( p < 0.05 for all; n = 6; Fig. 4A). The control IgG
antibody had no effect (Fig. 4A). Preincubation of the
nNav1.5 antibody with the immunization peptide for the
antibody blocked the antibody effect on adhesion (Fig. 4A).
The effect of combination treatments with SKF10047
(20 lM) and nNav1.5 antibody (20 ng/mL) was also mea-
sured. A significant difference in adhesion was not observed
for SW620 cells treated with SKF10047 or nNav1.5 antibody
alone or a combination of both (n= 6; Fig. 4B). Silencing the
Sigma-1 receptor in SW620 cells also reduced adhesion, and
application of nNav1.5 antibody (20 ng/mL) to the cells had
no further effect (n= 5; Fig. 4C). These results suggested that
the Sigma-1 receptor plays a significant role in the mecha-
nism of action of nNav1.5 in these cells.
nNav1.5 and Sigma-1 receptor expression
in SW620 cells
nNav1.5 protein was visualized in permeabilized cells in the
cytoplasm (Fig. 5A). When the cells were not permeabilized,
nNav1.5 staining was also observed (Fig. 5B). Since the
FIG. 3. Effect of Sigma-1
drugs on adhesion of SW620
cells. Cells were treated with
SKF10047 (A) or 5-methyl-
DMT (B) at concentrations
of 100, 20, 5, and 1 lM as
indicated for 24 h (n = 5 and
6, respectively). Adhesion to
collagen-coated plates was
quantified as absorbance at
570 nm after staining with
crystal violet. Following
Sigma-1 receptor silencing,
(C) cells were treated with
SKF10047 at a concentration
of 20 lM as indicated. Cel-
lular adhesion was deter-
mined in comparison with
cells transfected with a con-
trol silencing construct
(n= 5). A comparison of the
effect of 10 lM TTX was
made. Experiments with a
significant difference from
the control treatment are
marked with an asterisk
( p< 0.05). TTX, tetrodotoxin.
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nNav1.5 antibody binds to an extracellular domain, it is rea-
sonable to conclude that the nNav1.5 protein is expressed in
the plasma membrane and in the cytoplasm. Application of a
blocking peptide to nNav1.5 reduced the observed binding
of nNav1.5 antibody to the cells, indicating that the staining
observed was specific to nNav1.5 (n = 5). A Sigma-1 re-
ceptor antibody was utilized to confirm the expression of
Sigma-1 receptors in SW620 cells (Fig. 5C). Expression of
Sigma-1 receptors was observed although the antibody
could not distinguish between different localizations of the
receptor (n = 5).
nNav1.5 expression was verified in SW620 cells by
Western blotting of protein extracts. Expression was detected
at the expected size of*200 kDa (Fig. 6A). Sigma-1 receptor
protein expression and silencing were also investigated in
SW620 cells using Western blotting and an antibody to
Sigma-1 receptor. Sigma-1 receptor silencing vectors were
transfected into SW620 cells and after 48 h, silencing was
confirmed using Western blotting in comparison with a
control vector (Fig. 6B). Expression of Sigma-1 receptor was
confirmed by observation of a specific band at *25 kD.
Levels of silencing were quantified using a cell-based ELISA
in comparison with a control vector (n = 8; Fig. 6C). Gen-
erally, Sigma-1 receptor silencing of more than 80% was
obtained in experiments. Protein extracts were prepared from
SW620 cells and a mouse anti-Nav1.5 antibody was used to
immunoprecipitate the Nav1.5 protein and any proteins in a
complex with the Nav1.5 protein. The immunoprecipitates
were separated by SDS-PAGE and transferred to poly-
vinylidene difluoride membranes using Western blotting.
Sigma-1 receptor antibodies were able to detect a band at the
expected size of the Sigma-1, suggesting that Nav1.5 is in a
complex with the Sigma-1 receptor (n = 4; Fig. 6D). The
experiment was carried out with the Sigma-1 receptor anti-
body being used to pull down the Sigma-1 receptor and as-
sociated proteins from SW620 cell protein extracts. The
mouse anti-Nav1.5 antibody was able to detect the presence of
Nav1.5 in the Sigma-1 receptor immunoprecipitate although we
could not determine if this protein was specifically the neonatal
Nav1.5 protein (n= 4; Fig. 6E).
FIG. 4. Combination treatments with Sigma-1 drugs and nNav1.5 blocking antibody on adhesion of SW620 cells. The
ability of a polyclonal antibody to nNav1.5 to reduce the adhesion of SW620 cells was determined (A). Cells were incubated
with 100, 20, 5, and 1 ng/mL of nNav1.5 polyclonal antibody for 24 h (n = 6). Con-a consisted of 100 ng/mL of rabbit IgG in
phosphate-buffered saline containing azide. Con-b consisted of 20 ng/mL of nNav1.5 antibody preincubated with 100 lg/
mL of nNav1.5 peptide for 1 h at room temperature. The effect on adhesion of a combination of treatments with SKF10047
(50 lM) and nNav1.5 polyclonal antibodies (20 ng/mL) was determined following a 24-h treatment (n= 6) (B). The effect on
adhesion of a combination of Sigma-1 receptor gene silencing and nNav1.5 polyclonal antibodies (20 ng/mL) was deter-
mined (n= 5) (C). Experiments with a significant difference from the respective control treatment are marked with an
asterisk ( p < 0.05). Con-a, Control-a; Con-b, Control-b; IgG, immunoglobulin G.
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A combination of SKF10047 or 5-methyl-DMT and
Sigma-1 receptor gene silencing was utilized and the ef-
fect on the surface expression of nNav1.5 was determined
(Fig. 7A).
Treatment of SW620 cells with 50 lM SKF10047 or 5-
methyl-DMT for 48 h caused 52% and 53% reductions in
plasma membrane expression of nNav1.5 protein, respec-
tively (F= 207 p = 5.21 · 10-8; F = 170 p = 1.32 · 10-7). Si-
milar results were obtained from Sigma-1 receptor-silenced
cells with a reduction in surface expression of nNav1.5 of
53% compared with a gene silencing control (F= 611
p = 2.68· 10-10). Treatment of Sigma-1-silenced cells with
SKF10047 did not produce any significantly greater effect. It
was concluded that the Sigma-1 receptor increased the
plasma membrane expression of nNav1.5 in SW620 cells and
this was inhibited with Sigma drugs or gene silencing. Effect
of the above treatments on the total expression of nNav1.5
was also verified. No significant differences in total expres-
sion of nNav1.5 were observed (Fig. 7B).
Effect of hypoxia on Sigma-1 receptors
SW620 cells were cultured under normoxic or hypoxic
conditions for 24 h. Subsequently, the level of Sigma-1 re-
ceptor protein was ascertained using a cell-based ELISA with
antibodies to the Sigma-1 receptor. The results (Fig. 8A)
indicated that under hypoxic conditions, Sigma-1 protein
levels increased by more than sixfold, which was found to be
significant (F= 188 p = 1.62 · 10-9; n= 8). To verify that
hypoxia had been induced, the cells were also stained for Hif-
1 alpha expression. The data (Fig. 8B) indicated that Hif-1
alpha was increased 3.71-fold, which was significant (F= 12
p = 0.0034; n = 8). Cells were also tested for viability, but no
significant change in viability was observed between nor-
moxic and hypoxic cells (data not shown). Some changes in
proliferation were observed between normoxic and hypoxic
conditions (*12% overall) and, as such, all fluorescence
values were adjusted based on the change in proliferation.
Using the same assay, SW620 cells were also tested for the
levels of total nNav1.5 protein. The data (Fig. 8C) indicated a
significant 2.08-fold increase in total nNav1.5 protein under
hypoxic conditions (F = 43 p= 1.27 · 10-5; n = 8). This in-
crease was not significantly affected by the application of
SKF10047 for 24 h. A significant increase in surface nNav1.5
(by 2.02-fold) was also recorded (Fig. 8D) when comparing
normoxic and hypoxic conditions (F = 43 p = 1.26· 10-5;
n = 7). Interestingly, application of SKF10047 for 24 h re-
sulted in a significant decrease in nNav1.5 levels (F = 20
p = 4.81 · 10-4; n= 8) approaching the level found under
normoxic conditions.
Discussion
It has been well documented that Sigma-1 receptor drugs
are capable of changing the invasive aspects of cancer cells
(for a review, Aydar et al.15), however, the exact mechanisms
have remained unclear. Another well-documented aspect of
Sigma-1 receptors is their ability to interact with a number of
different ion channels.21–23 In MDA-MB-231 cells, VGSC
current density was modulated by Sigma-1 receptors.24 Pre-
viously, it was described that modulation of Sigma-1 recep-
tors in breast cancer cell lines can affect their invasive
potential and that this effect was mediated via expression of
nNav1.5. VGSC (nNav1.5) upregulation occurs in metasta-
tic breast and colon cancer cells and this promotes the cell
invasive properties.4,6,13,28
Sigma-1 receptors form a complex with VGSCs in
breast cancer cells,24 which was further substantiated by
FIG. 5. Expression of nNav1.5
and Sigma-1 receptor expression in
SW620 cells. (A) Permeabilized
SW620 cells probed with anti-
bodies to nNav1.5. (i) nNav1.5
antibody; (ii) peptide blocked an-
tibodies; (iii) control IgG antibody.
(B) Live stained SW620 cells pro-
bed with antibodies to nNav1.5. (i)
nNav1.5 antibody; (ii) peptide
blocked antibodies; (iii) control
IgG antibody. (C) Permeabilized
SW640 cells probed with antibodies
to Sigma-1 receptor. (i) Sigma-1 re-
ceptor antibody; (ii) peptide blocked
antibodies; (iii) control IgG anti-
body. Size bar represents 20lm
(n= 5).
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FIG. 7. Effect of Sigma-1 receptor on surface expression of nNav1.5 in SW620 cells. (A) Cells were treated with
SKF10047 or DMT at a concentration of 50 lM for 48 h or the Sigma-1 receptor was gene silenced and subsequently the
surface expression of nNav1.5 was determined by probing with an antibody to nNav1.5 in live cells (n= 12). (B) In addition,
combination treatments with both SKF10047 and Sigma-1 gene silencing were carried out. Surface expression of nNav1.5
was quantified using a fluorescent plate reader and expressed as RFU. Experiments with a significant difference from the
respective control treatments are marked with an asterisk ( p< 0.05). In addition, the total expression of nNav1.5 in SW620
cells under the same experimental conditions was verified (n = 12).
FIG. 6. Expression of nNav1.5 and Sigma-1 receptor in SW620, and immunoprecipitation between Nav1.5 and Sigma-1
receptor. (A) Western blot of SW620 cells probed with antibodies to nNav1.5 and actinin (n= 4). Position of size markers at
200 and 96 kDa is shown. (B) Western blot of SW620 cells probed with antibodies to Sigma-1 receptor and actinin (n= 4).
Cells are transfected with a Sigma-1 receptor silencing vector or a control plasmid. Position of size markers at 96 and 30 kDa is
indicated. (C) Quantification of gene silencing of Sigma-1 receptors in SW620 cells. Cell-based ELISA data from Sigma-1
receptor gene-silenced and control cells (n= 8). (D) Immunoprecipitation of Nav1.5 by Sigma-1 receptor antibodies. Whole-
cell extract, immunoprecipitation with Nav1.5 antibodies, and immunoprecipitation with a control IgG antibody are shown
(n= 3). Position of size markers at 200 kDa is shown. (E) Immunoprecipitation of Sigma-1 receptor by Nav1.5 antibodies.
Whole-cell extract, immunoprecipitation with Nav1.5 antibodies, and immunoprecipitation with a control IgG antibody are
shown (n= 3). Position of size markers at 30 kDa is shown. ELISA, enzyme-linked immunosorbent assay. Experiments with a
significant difference from the respective control treatments are marked with an asterisk (p< 0.05).
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experiments indicating functional complexes existing be-
tween Sigma-1 receptors and VGSCs, which are capable of
increasing the plasma membrane expression of VGSCs and
increasing the invasive properties of breast cancer cells at
least by modulating the adhesiveness of cells to the extra-
cellular matrix.14
We aimed in this study to investigate a possible functional
link between Sigma-1 receptors and nNav1.5 in colon cancer
cells and to investigate whether the effects of Sigma-1 drugs
in altering the invasive behavior of colon cancer cells oc-
cur by an interaction with nNav1.5. As reported previously,6
colon cancer cells express nNav1.5 predominantly. Expres-
sion of nNav1.5 was documented in this study by both
Western blotting and immunostaining and was found both in
the cytoplasm and at the plasma membrane surface due to
the use of an antibody that binds to an extracellular domain
of nNav1.5. Expression of the Sigma-1 receptor was docu-
mented by both Western blotting and immunostaining.
However, the antibody utilized was unable to distinguish the
exact cellular localization in these cells.
An effect of Sigma-1 drugs on proliferation was only found
at higher concentrations of Sigma-1 drugs. We speculate that
at these higher drug concentrations, the Sigma-2 receptor
may also be affected. In addition, only a modest reduction in
migration was observed, although it is possible that pre-
treatment of the cells with Sigma drugs may increase these
values. We found that Sigma-1 receptor drugs were able to
significantly alter the adhesiveness of metastatic colon cancer
cell line SW620 to collagen, an important factor in inva-
siveness. Gene silencing of the Sigma-1 receptor signifi-
cantly decreased the adhesion of these cells. This observed
effect on adhesion was proposed to be via the drugs acting on
the Sigma-1 receptor as no further effect on adhesion was
observed when the Sigma-1 receptor was silenced or Sigma-1
drugs were applied. We observed that application of an an-
tibody that binds and blocks the nNav1.5 channel in breast
cancer cells and reduces the adhesion of those cells was also
capable of reducing the adhesion of SW620 cells, further
documenting the importance of nNav1.5 in the invasive
properties of these cells, which was recently documented.6
The Sigma-1 receptor was found to be in a complex with
Nav1.5 in these cells using immunoprecipitation, although in
these particular experiments it was not possible to distinguish
between the adult form of Nav1.5 and the neonatal form.
Previously, it was demonstrated that the Sigma-1 receptor
binds directly to Nav1.5 with fourfold symmetry, suggesting
that the Sigma-1 receptor interacts with the transmembrane
regions of its partners. Also, two other Sigma-1 ligands,
haloperidol and (+)-pentazocine, disrupted this interaction
both in vitro and in living cells.24
FIG. 8. Effect of hypoxia on Sigma-1 receptor expression and surface expression of nNav1.5 in SW620 cells. SW620
cells were transferred to a hypoxia incubator for 24 h and the levels of Sigma-1 receptor protein (A; n = 8), Hif-1 (B, n = 8),
and total nNav1.5 (C; n = 7) were quantified and compared with cells under normal culture conditions using a cell-based
ELISA. In the case of nNav1.5, cells under hypoxic conditions were treated with SKF10047 and compared with hypoxic
cells without SKF10047. In similar experiments, (D) cells were also live-stained and tested for the presence of surface
nNav1.5. Following all experimental conclusions, the cells were stained with a crystal violet assay to account for differences
in cell proliferation and potential loss of cells due to altered adhesion. Fluorescence values were adjusted accordingly.
Experiments with a significant difference from the respective control treatments are marked with an asterisk (p < 0.05).
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Sigma-1 receptor gene silencing or treatment with Sigma-
1 receptor drugs resulted in a clear reduction in the sur-
face expression of nNav1.5 although neither treatment
caused a reduction in the total amount of nNav1.5. Hypoxia is
known to be a major driving force in the switch from cells
becoming invasive. The effect of hypoxia on Sigma-1 re-
ceptor expression in SW620 has been previously reported.29
Our results are in agreement indicating a significant rise
in Sigma-1 receptor expression under hypoxic conditions.
The effect of hypoxia on nNav1.5 total expression was de-
termined and we observed an approximate twofold increase
in nNav1.5 expression. Similar experiments were carried
out,6 although in this case the experimenters did not see an
increase in nNav1.5. However, our experiments utilized a
cell-based assay that is more likely to measure small changes
in protein levels and utilizes a higher number of repeat ex-
periments.
Application of Sigma-1 drugs did not affect the total ex-
pression of nNav1.5 under hypoxic conditions. However,
it did effect the expression of surface expressed nNav1.5,
lowering the level of surface nNav1.5 to the levels seen
in normoxic cells. Our interpretation is that under hypoxic
conditions, Sigma-1 receptor expression is upregulated to
promote survival of the cell. One of the ‘‘client’’ proteins of
the Sigma-1 receptor is the nNav1.5 protein, which is also
upregulated. The interaction between the Sigma-1 recep-
tor and nNav1.5 results in increased surface expression of
nNav1.5, which increases the invasiveness of the cells via
an increase in adhesion and migration. The Sigma-1 receptor
is hypothesized to be ‘‘silent’’ under normal conditions, and
only comes to play on cell physiology when the cell is under
‘‘stress’’ such as upon disease.
In this case, Sigma-1 receptors act as a ‘‘chaperone’’
trafficking ion channels to the plasma membrane affecting
the electrical plasticity of the cell.25 This interaction likely
occurs early in invasion as VGSC expression affects a net-
work of genes controlling invasiveness in colon cancer.7
There is evidence to support this idea as a protein interaction
between Sigma-1 receptors and Kv1.2 channels was induced
upon cocaine exposure. This resulted in a redistribution of
both proteins to the plasma membrane.30
We speculate that hypoxia-driven increases in levels of
the Sigma-1 receptor as reported previously29 in colon cancer
cell lines may result in an increase of the plasma membrane
expression of nNav1.5 by the Sigma-1 receptor acting as a
chaperone protein. Coupled with this is the previously dem-
onstrated hypoxia-driven upregulation of nNav1.5 in SW620
cells,6 culminating in colon cancer cells with an increased
invasive potential, possibly to ‘‘escape’’ their hypoxic con-
ditions resulting eventually in metastasis. Importantly, we
acknowledge that these experiments have been performed on
one model cell line. It would be essential in the future to
investigate this mechanism further in a variety of other colon
cancer cell lines.
Conclusions
The Sigma-1 receptor appears to play an important role in
VGSC delivery to the plasma membrane and this has clinical
implications, given the prominent involvement of nNav1.5 in
metastatic disease.11,31
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